Greenwich LifeSciences (GLSI) Long-Term Debt Issuances (2021 - 2022)
Greenwich LifeSciences' (GLSI) quarterly Long-Term Debt Issuances came in at $2.0 million in Q2 2022, up 1585.42% YoY from $120000.0 in Q2 2021, and down 63.32% on a QoQ basis from $5.5 million in Q1 2022.
Powered by 
Analysis
Greenwich LifeSciences (GLSI) Long-Term Debt Issuances (2021 - 2022) Analysis & Trends
Greenwich LifeSciences (GLSI) has 2 years of Long-Term Debt Issuances data on file, last reported at $2.0 million in Q2 2022.
- Quarterly Long-Term Debt Issuances rose 1585.42% year-over-year to $2.0 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $7.0 million (changed N/A YoY) and the FY2021 annual result came in at -$275154.0, down 176.43% from the prior year.
- Long-Term Debt Issuances eased to $2.0 million in Q2 2022, from $5.5 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $5.5 million in Q1 2022 to a low of -$550308.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Greenwich LifeSciences | 231.59 Mn | 231.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 2.02 Mn |
| Mar 31, 2022 | 5.51 Mn |
| Dec 31, 2021 | -550,308.00 |
| Jun 30, 2021 | 120,000.00 |
| Mar 31, 2021 | 275,154.00 |